このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)

2026年9月11日 更新者:Gilead Sciences

16歳以上のシスジェンダー男性、トランスジェンダー女性、トランスジェンダー男性、およびジェンダー非バイナリーの人々におけるHIV暴露前予防のための、年2回の長期作用型レナカパビル皮下注射の有効性と安全性を評価する第3相、二重盲検、多施設、無作為化試験男性パートナーとセックスをし、HIV 感染のリスクがある年齢

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.

The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

調査の概要

研究の種類

介入

入学 (実際)

3292

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • UAB Sexual Health Research Clinic
    • California
      • Loma Linda、California、アメリカ、92354
        • Loma Linda University Clinical Trial Center Clinic
      • Los Angeles、California、アメリカ、90069
        • Mills Clinical Research
      • Los Angeles、California、アメリカ、90036
        • Ruane Clinical Research Group Inc.
      • Los Angeles、California、アメリカ、90038
        • UCLA CBAM Vine Street Clinic
      • Los Angeles、California、アメリカ、90059
        • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
      • Los Angeles、California、アメリカ、90502
        • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      • Palm Springs、California、アメリカ、92262
        • BIOS Clinical Research
      • San Diego、California、アメリカ、92103
        • UCSD Anti Viral Research Center
      • San Francisco、California、アメリカ、94102
        • Optimus Medical Group
      • San Francisco、California、アメリカ、94102
        • Bridge HIV at the San Francisco Department of Public Health
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University of Colorado Clinical and Translational Research Centers (CTRC)
    • Connecticut
      • New Haven、Connecticut、アメリカ、06510
        • Yale University, School of Medicine
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20009
        • Whitman-Walker Institute Inc.
      • Washington D.C.、District of Columbia、アメリカ、20017
        • Washington Health Institute
    • Florida
      • Fort Lauderdale、Florida、アメリカ、33308
        • Therafirst Medical Center
      • Fort Lauderdale、Florida、アメリカ、33316
        • Gary Richmond, MD, PA
      • Ft. Pierce、Florida、アメリカ、34982
        • Midway Immunology & Research Center, LLC
      • Jacksonville、Florida、アメリカ、32207
        • CAN Community Health Clinic
      • Miami、Florida、アメリカ、33136
        • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
      • Miami Gardens、Florida、アメリカ、33055
        • CAN Community Health
      • Orlando、Florida、アメリカ、32803
        • Orlando Immunology Center
      • Sarasota、Florida、アメリカ、34237
        • CAN Community Health
    • Georgia
      • Atlanta、Georgia、アメリカ、30303
        • Emory University
      • Atlanta、Georgia、アメリカ、30308
        • Emory University Hospital Midtown Infectious Disease Clinic
      • Atlanta、Georgia、アメリカ、30030
        • The Hope Clinic at Emory University
    • Illinois
      • Chicago、Illinois、アメリカ、60613
        • Howard Brown Health Center
      • Chicago、Illinois、アメリカ、60612
        • RMR Core Center
      • Chicago、Illinois、アメリカ、60612
        • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University Infectious Diseases Research
    • Kentucky
      • Lexington、Kentucky、アメリカ、40503
        • Baptist Health Lexington
      • Louisville、Kentucky、アメリカ、40241
        • Norton Infectious Disease Specialists
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70119
        • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Johns Hopkins University School of Medicine
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • The Fenway Institute
    • Michigan
      • Berkley、Michigan、アメリカ、48072
        • Be Well Medical Center
      • Detroit、Michigan、アメリカ、48202
        • Henry Ford Hospital
    • Mississippi
      • Jackson、Mississippi、アメリカ、39202
        • Open Arms Healthcare Center
    • Missouri
      • Kansas City、Missouri、アメリカ、64111
        • KC CARE Health Center
    • New Jersey
      • Newark、New Jersey、アメリカ、07102
        • St. Michael's Medical Center
      • Somers Point、New Jersey、アメリカ、08244
        • South Jersey Infectious Disease
    • New York
      • New York、New York、アメリカ、10029
        • Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27514
        • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
      • Greensboro、North Carolina、アメリカ、27401
        • Cone Health/Regional Center for Infectious Disease Research Center
      • Winston-Salem、North Carolina、アメリカ、27103
        • Wake Forest University Health Sciences
    • Ohio
      • Cincinnati、Ohio、アメリカ、45267
        • University of Cincinnati
      • Columbus、Ohio、アメリカ、43210
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • Penn Prevention Unit
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Medical University of South Carolina, Infectious Disease Clinic
      • Columbia、South Carolina、アメリカ、29203
        • Prisma Health-Midlands Clinical Research Unit
      • Greenville、South Carolina、アメリカ、29605
        • Prisma Health Internal Medicine Clinic
    • Tennessee
      • Memphis、Tennessee、アメリカ、38105
        • St Jude Children's Research Hospital
      • Memphis、Tennessee、アメリカ、38103
        • Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
      • Nashville、Tennessee、アメリカ、37208
        • Meharry Medical College Clinical and Transitional Research Center
    • Texas
      • Austin、Texas、アメリカ、78705
        • Central Texas Clinical Research
      • El Paso、Texas、アメリカ、79915
        • Centro San Vincente
      • Houston、Texas、アメリカ、77098
        • The Crofoot Research Center, INC
      • Houston、Texas、アメリカ、77009
        • UT Health Science Center at Houston
    • Washington
      • Seattle、Washington、アメリカ、98104
        • Ofiice of Dr. Peter Shalit, MD
      • Buenos Aires、アルゼンチン、1072
        • Hospital General de Agudos JM Ramos Mejia
      • Buenos Aires、アルゼンチン、B7600
        • Instituto de Investigaciones Clinicas Mar del Plata
      • Buenos Aires、アルゼンチン、1202
        • Fundacion Huesped
      • Bangkok、タイ、10330
        • King Chulalongkorn Memorial Hospital
      • Bangkok、タイ、10400
        • Ramathibodi Hospital, Mahidol University
      • Bangkok、タイ、10330
        • Institute of HIV Research and Innovation
      • Bangkok、タイ、10330
        • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
      • Chiang Mai、タイ、50200
        • Research Institute for Health Sciences, Chiang Mai University
      • Khon Kaen、タイ、40002
        • Srinagarind Hospital, Khon Kaen University
      • Nonthaburi、タイ、11000
        • Bamrasnaradura Infectious Disease Institute
      • Belo Horizonte - MG、ブラジル、30130-100
        • Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
      • Canela-Salvador、ブラジル、40110-060
        • Fundação Bahiana de Infectologia
      • Manauas、ブラジル、69040-000
        • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
      • Nova Iguaçu、ブラジル、26030-380
        • Hospital General de Nova Iguaçu - HGNI
      • Porto Alegre、ブラジル、RS 91350 200
        • Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
      • Rio de Janeiro、ブラジル、21040-360
        • Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
      • São Paulo、ブラジル、01246-903
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
      • São Paulo、ブラジル、04121-000
        • Centro de Referência e Treinamento DST/AIDS
      • São Paulo、ブラジル、06519-332
        • Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
    • PR
      • San Juan、PR、プエルトリコ、00717
        • Ararat Research Center
      • San Juan、PR、プエルトリコ、00909
        • Centro Ararat- San Juan
      • Barranco、ペルー、15063
        • Asociacion Civil Impacta Salud y Educacion - Sede Barranco
      • Callao、ペルー、7006
        • Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
      • Iquitos、ペルー
        • Asociacion Civil Selva Amazonica
      • Lima、ペルー、15001
        • Via Libre
      • Lima、ペルー、15088
        • Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
      • Guadalajara C.P.、メキシコ、44160
        • Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
      • Cape Town、南アフリカ、7925
        • Desmond Tutu Health Foundation
      • Johannesburg、南アフリカ、2038
        • Wits Reproductive Health and HIV Institute (Wits RHI)
      • Pretoria、南アフリカ、87
        • The Aurum Institute: Pretoria Clinical Research Centre
      • Soshanguvhe、南アフリカ、0152
        • Setshaba Research Centre
      • Tembisa、南アフリカ、1632
        • The Aurum Institute Tembisa CRC, Clinic 4
      • Vincent、南アフリカ、5217
        • FPD-DTHF Ndevana Commuity Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

16年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Key Inclusion Criteria:

Incidence Phase

  • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.

  • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.

  • Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

    • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
    • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
    • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

  • Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

  • Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
  • Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

  • Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks
  • Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily
  • Oral LEN 600 mg on Days 1 and 2

Participants will receive oral LEN if SC injections are not available.

Tablets administered orally without regard to food

他の名前:
  • GS-6207

Administered via SC injections

他の名前:
  • GS-6207; Yeztugo

Tablets administered orally

実験的:Randomized Blinded Phase: Placebo LEN + F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • SC LEN placebo every 26 weeks
  • Oral F/TDF 200/300 mg once daily
  • PTM Oral LEN on Days 1 and 2

Participants will receive oral LEN placebo if SC injections are not available.

Tablets administered orally

他の名前:
  • ツルバダ®

Administered via SC injections

Tablets administered orally

実験的:LEN Open-Label Extension (OLE) Phase

Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase.

Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days).

Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2.

All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first.

After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.

Tablets administered orally without regard to food

他の名前:
  • GS-6207

Administered via SC injections

他の名前:
  • GS-6207; Yeztugo
実験的:Pharmacokinetic (PK) Tail Phase

Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days).

Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.

Tablets administered orally

他の名前:
  • ツルバダ®

F/TAF tablets administered orally once daily

他の名前:
  • デスコビ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
時間枠:Incidence Phase Screening Visit (Day 1)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood.

HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:

  • Positive HIV-1/2 differentiation Ab, OR
  • Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR
  • HIV-1 RNA quantitative test ≥200 copies/mL.
Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
時間枠:Up to 149 weeks

HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Up to 149 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
時間枠:Up to 149 weeks

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
時間枠:Up to 149 weeks

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Up to 149 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
時間枠:First dose date up to 184 weeks

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

First dose date up to 184 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
時間枠:First dose date up to 184 weeks

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

First dose date up to 184 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Gilead Study Director、Gilead Sciences

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年6月28日

一次修了 (実際)

2024年8月21日

研究の完了 (推定)

2028年8月1日

試験登録日

最初に提出

2021年5月28日

QC基準を満たした最初の提出物

2021年6月11日

最初の投稿 (実際)

2021年6月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年9月11日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する